

University of Groningen

Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI)

Bodewes, Frank A.J.A.; Freeman, Alvin Jay; Weymann, Alexander; Debray, Dominique; Scheers, Isabelle; Verkade, Henkjan J.; Narkewicz, Michael R.

Published in:
Journal of Pediatric Gastroenterology and Nutrition

DOI:
[10.1097/MPG.0000000000003944](https://doi.org/10.1097/MPG.0000000000003944)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2024

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Bodewes, F. A. J. A., Freeman, A. J., Weymann, A., Debray, D., Scheers, I., Verkade, H. J., & Narkewicz, M. R. (2024). Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position Paper. *Journal of Pediatric Gastroenterology and Nutrition*, 78(1), 153-165. <https://doi.org/10.1097/MPG.0000000000003944>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position Paper

*Frank A.J.A. Bodewes, †A. Jay Freeman, ‡Alexander Weymann, §Dominique Debray, ¶Isabelle Scheers, *Henkjan J. Verkade, and ¶Michael R. Narkewicz

ABSTRACT

The broad spectrum of hepatobiliary involvement in cystic fibrosis (CF) has been commonly referred to as cystic fibrosis liver disease (CFLD). However, differences in the definitions of CFLD have led to variations in reported prevalence, incidence rates, and standardized recommendations for diagnosis and therapies.

Harmonizing the description of the spectrum of hepatobiliary involvement in all people with CF (pwCF) is deemed essential for providing a reliable account of the natural history, which in turn supports the development of meaningful clinical outcomes in patient care and research.

Recognizing this necessity, The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) commissioned and tasked a committee to develop and propose a systematic classification of the CF hepatobiliary manifestations to increase uniformity, accuracy, and comparability for clinical, registry, and research purposes. This report describes the committee's combined expert position statement on hepatobiliary involvement in CF, which has been endorsed by NASPGHAN and ESPGHAN.

We recommend using CFHBI (Cystic Fibrosis Hepato-Biliary Involvement) as the updated term to describe and classify all hepatobiliary manifestations in all pwCF. CFHBI encompasses the current extensive spectrum of phenotypic, clinical, or diagnostic expressions of liver involvement observed in pwCF. We present a schematic categorization of CFHBI, which may also be

used to track and classify the changes and development of CFHBI in pwCF over time. The proposed classification for CFHBI is based on expert consensus and has not been validated for clinical practice and research purposes. Achieving validation should be an important aim for future research.

Key Words: ALT, APRI, AST, biliary disease, CFLD, cirrhosis, cystic fibrosis, elastography, FIB, GGT, heterogeneous, homogeneous, liver, liver enzymes, liver stiffness, malignancy, MRI, nodular, non-cirrhotic, portal hypertension, splenomegaly, steatosis, ultrasound

(*JPGN* 2024;78: 153–165)

During an expert meeting held in January 2016 at a European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) monothematic conference on cystic fibrosis-related liver disease (CFLD), the need for a universal consensus on the definition of CFLD to clarify disease stages and identify relevant biomarkers for assessing severity was emphasized. This initiative aimed to achieve a transatlantic agreement between major professional associations, ESPGHAN and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), on a consensus definition and classification system critical for addressing epidemiology and the natural course of the disease. A deeper understanding of the pathophysiology and

Received June 29, 2022; accepted August 8, 2023.

From the *Division of Pediatric Gastroenterology/Hepatology, Beatrix Children's Hospital/University Medical Center Groningen, University of Groningen, Groningen, Netherlands, the †Division of Gastroenterology, Hepatology and Nutrition, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, the ‡Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, OH, the §Pediatric Hepatology Unit, Assistance Publique-Hôpitaux de Paris (APHP)-Hôpital Necker-Enfants maladies, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France, the ¶Pediatric Gastroenterology, Hepatology and Nutrition Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, and the ¶Digestive Health Institute, Children's Hospital Colorado and Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO.

Address correspondence and reprint requests to Frank A.J.A. Bodewes, MD, Division of Pediatric Gastroenterology/Hepatology, Beatrix Children's Hospital/University Medical Center Groningen, University of Groningen, Groningen, Netherlands (e-mail: f.a.j.a.bodewes@umcg.nl).

CME module may be found at <https://learnonline.naspgan.org/jpgn2>

Disclaimer: See complete disclaimers on page 165.

Dr Bodewes served on medical advisory board for Vertex Pharmaceuticals and has research funding from the European Society for Paediatric Gastroenterology Hepatology and Nutrition and the Dutch CF Foundation. Dr Narkewicz serves as a consultant for Vertex and has research funding from Gilead and AbbVie and the Cystic Fibrosis Foundation. Dr Scheers has research funding from Fondation Contre le Cancer, Salus Sanguinis, and Fond National pour la Recherche Scientifique. Dr Debray serves as a consultant for Alexion Pharmaceuticals and Orphan, and has research funding from Vaincre la Mucoviscidose. Dr Verkade has served as consultant for Ausnutria, Albireo, Mirum, Friesland Campina, Vivet, Intercept, GMP-Orphan, and Shire, and his University Medical Center received compensation from Vertex for a tutorial contribution. Dr Freeman receives research funding from the Cystic Fibrosis Foundation, National Institutes of Health, AbbVie, and Travere Therapeutics. He has served as a consultant for AbbVie and Takeda. The remaining author reports no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpgn.org).

Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

DOI: 10.1097/MPG.0000000000003944

What Is Known

- Hepatobiliary involvement is common in people with cystic fibrosis (CF).
- The manifestations of hepatobiliary involvement can significantly vary in form, extent, and severity among people with CF (pwCF).
- The presently commonly utilized term “cystic fibrosis liver disease” (CFLD) is not comprehensive enough to accurately encompass all the liver and biliary involvement observed in pwCF.

What Is New

- We recommend using CFHBI (Cystic Fibrosis Hepato-Biliary Involvement) as the up-to-date all-encompassing term for all liver and biliary presentations in all pwCF.
- CFHBI encompasses the full range of phenotypical, clinical, and biochemical presentations of liver and biliary involvement in pwCF.
- We provide a comprehensive, structured categorization for CFHBI that may also be used to track and document the progression of CFHBI in pwCF over time.
- We recommend using this new classification system for CFHBI in pwCF to enhance uniformity, accuracy, and comparability in clinical, registry, and research contexts.

prognostic factors for the long-term evolution of CFLD is fundamental to move forward and has a strong bearing on identifying potential treatments (1). A joint expert committee (that includes all authors of this manuscript) composed of members of Hepatology committee and the Pancreas-CF Special interest group of ESPGHAN and NASPGHAN members with a special interest in CFLD was convened to evaluate the current classification and nomenclature for CF hepatobiliary involvement (CFHBI) for clinical, registry, and research use, and if appropriate, propose a revised classification system. Recommendations for this classification as a combined expert statement, was subsequently accepted according to established approval procedures as a combined societal position paper by both NASPGHAN and ESPGHAN.

The broad spectrum of hepatobiliary involvement in people with CF (pwCF) has been commonly referred to as CFLD. During follow-up, hepatobiliary involvement may occur in 80%–90% of pwCF, of which approximately 10% are severe and affect outcomes (2,3). However, for some signs currently included in the term CFLD, it is unknown if they represent actual liver disease or merely epiphenomena of limited clinical relevance. Moreover, the pathophysiology and the correlation between different hepatobiliary manifestations in pwCF and their clinical consequences are not fully known. Due to a lack of a uniform definition of CFLD, there are discrepancies in reported prevalence and incidence rates and variations in the suggested diagnostic and treatment approaches for the various types of liver involvement in pwCF.

THE LIVER IN THE ERA OF CFTR MODULATOR THERAPIES

Currently, proven, effective therapy for the liver involvement in pwCF is lacking. Ursodeoxycholic acid (UDCA) has been used

in the absence of randomized trials to treat CFLD and to attempt to prevent the development of advanced liver disease in pwCF. However recent large nonrandomized cohort studies suggest that it is not effective in the prevention of the development of advanced liver disease in pwCF (4–6). In recent years, various CF transmembrane regulator (CFTR) directed modulator therapies have become available for pwCF. It is reasonable to assume that these therapies may impact the liver and liver pathology in pwCF, with potential beneficial effects or unintended hepatic side effects. Therefore, it is crucial that clinical studies evaluate the safety and efficacy of CFTR modulator therapies in relation to hepatobiliary involvement. Similar concerns may arise with other liver-specific therapies for pwCF. To systematically evaluate the impact of these therapies on CFHBI, a universally accepted classification of liver involvement in pwCF is necessary.

METHODS

Regarding the composition of the committee, representatives were suggested by NASPGHAN Hepatology and Pancreas committees and approved, and ESPGHAN appointed members from the Hepatology committee and the special interest group on CF and Pancreas. All members of the committee took part in the committee meetings regarding the basic concept and outline of the current position paper. Each member of the committee was the primary reviewer for one subheading of the manuscript based on their individual expertise. All committee members reviewed and approved the manuscript.

The consensus process involved several stages, including initial discussions through email correspondence, teleconferences, and a joint meeting where the purpose, main characteristics, and structure of the classification were discussed and recorded. Each committee member was assigned to a specific aspect of the classification system to review the relevant literature and draft the relevant section, ensuring equal participation and diverse perspectives. One author (FAJAB) compiled the drafts into a cohesive document, which the entire committee then reviewed and provided feedback on through email correspondence and teleconferences. Revisions were made based on feedback, and the process continued until consensus was reached among all committee members. The draft manuscript was circulated to ESPGHAN members, including the Hepatology committee and the ESPGHAN special interest group on CF and Pancreas for comments and review.

The committee initially reviewed and discussed the current published definitions of CFLD (Table 1). The Colombo (7), Debray (8), and Koh (9) criteria focus on clinical signs for disease classification, while the Flass (10) criteria is a phenotypic classification. The classification of Colombo and Debray targeted identification of pwCF for potential therapeutic interventions, in particular the use of UDCA, the Flass and Koh classifications were primarily intended for evaluation of natural history and use in research.

In the following consensus process, literature was reviewed considering the present relevant hepatic manifestations and signs in pwCF and their potential significance for the revised classification. The joint committee deliberated on this information and proposed an alternative classification system that encompasses key physical examination findings, commonly available laboratory values, liver imaging findings, liver stiffness measurements (LSM), and liver histology associated with clinically significant hepatobiliary outcomes. The summary boxes at the end of each paragraph represent the committee's current understanding of the topics discussed, based on existing knowledge, and are intended to support future research and help develop improved recommendations for managing CFHBI.

TABLE 1. A summary of the presently available published definitions for CFLD

Colombo	2002	CFLD considered if at least 2 of the following conditions present on at least 2 consecutive examinations spanning a 1-year period: <ol style="list-style-type: none"> 1. Clinical hepatomegaly (increase in liver span and consistency, with liver edge palpable more than 2 cm below the costal margin in the mid-clavicular line), confirmed by ultrasonography 2. Abnormal serum liver enzyme levels consisting of elevation above the upper normal limits of 2 of the following: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma glutamyl transferase (GGT) 3. Ultrasound abnormalities other than hepatomegaly (ie, increased, heterogeneous echogenicity, nodularity, irregular margins, splenomegaly) <i>Ultrasonographic pattern of steatosis and liver biopsy were not included in the definition</i>
Debray	2011	Diagnosis of CFLD should be considered if 2 or more categories are present: <ol style="list-style-type: none"> 1. Physical examination: hepatomegaly: >2 cm below the costal margin on the mid-clavicular line, confirmed by ultrasonography, and/or splenomegaly, confirmed by ultrasound 2. Serum blood tests: increase of transaminases and GGT above upper limits of normal at least 3 consecutive determinations over 12 months after excluding other causes of liver disease 3. Radiologic testing: ultrasonographic evidence of liver involvement or portal hypertension or biliary abnormalities 4. Liver biopsy demonstrates abnormal hepatobiliary histology
Flass	2013	Classification of CFLD <ol style="list-style-type: none"> 1. CF related liver disease with cirrhosis/portal hypertension (based on clinical exam/imaging, histology, laparoscopy) 2. Liver involvement without cirrhosis/portal hypertension consisting of at least one of the following: <ol style="list-style-type: none"> a. Persistent AST, ALT, GGT > 2 times upper limit of normal b. Intermittent elevations of the above laboratory values c. Steatosis (histologic determination) d. Fibrosis (histologic determination) e. Cholangiopathy (based on ultrasound, MRI, CT, ERCP) f. Ultrasound abnormalities not consistent with cirrhosis 3. Preclinical: No evidence of liver disease on exam, imaging, or laboratory values
Koh	2017	Diagnosis of CFLD should be considered if 2 or more categories are present: <ol style="list-style-type: none"> 1. Liver biopsy demonstrating pathology or 2. Radiologic evidence demonstrating diffuse liver disease or cirrhosis 3. At least 2 persistently abnormal: ALT, AST, GGT, or ALP 4. Evidence of hepatomegaly, splenomegaly, or portal hypertension by imaging 5. Abnormal vibration controlled transient elastography (VCTE) on FibroScan® at any time 6. Persistently abnormal APRI, FIB-4, or AST-to-ALT ratio (AAR) <i>Persistently abnormal was defined as having abnormal values on multiple dates over at least 2 consecutive years</i>

APRI = AST to platelet index; CFLD = cystic fibrosis liver disease; CT = computed tomography, ERCP, endoscopic retrograde cholangiopancreatography; MRI = magnetic resonance imaging.

CFHBI IN PWCF

The joint committee recommends the use of “Cystic Fibrosis Hepatobiliary Involvement” (CFHBI) to refer to all liver and biliary tract-related signs, clinical and/or biochemical diagnostic findings observed in pwCF.

The proposed CFHBI classification will aid in:

- Understanding the progression of CFHBI over time.
- Establishing links between various manifestations of CFHBI, such as whether steatosis can lead to severe liver disease in certain cases.
- Assessing and evaluating the potential impact of treatments for pwCF on CFHBI.

Table 2 provides a detailed description of the CFHBI classification based on different elements, including biochemistry, imaging, histology, LSM, and clinical signs.

HEPATOBIILIARY INVOLVEMENT IN PWCF

Elevation of Liver Enzymes (E)

Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transpeptidase (GGT) are frequently assessed as part of standard follow-up. For pwCF, there has been an ongoing debate about whether elevated liver enzyme levels are useful biomarkers or predictors of the structural liver involvement in pwCF. The finding of elevated liver enzymes in pwCF must be

evaluated considering factors such as recurrent respiratory infections, nutritional issues (including malnutrition and obesity), and potential drug-induced liver injury.

AST and ALT

Elevated transaminases are a frequent finding in pwCF (2). A study conducted on children diagnosed with CF through newborn screening revealed that a persistent elevation of AST or GGT >1.5 × ULN (upper limit of normal) before the age of 5 was linked to a 6-fold increase in the risk of identifying the clinically significant liver disease, defined as the presence of cirrhosis, portal hypertension (PHT), or stage F3/4 fibrosis on liver biopsy (2). Patriquin et al (11) also reported a correlation between elevated AST levels and the appearance of signs of cirrhosis on liver ultrasound (US). Ling et al (12) conducted a recent study on 244 children with CF, which reported higher mean ALT/AST levels in children and adolescents having liver US abnormalities compared to those without such imaging abnormalities. However, the transaminase levels were mostly within the normal range, and there was a significant overlap in those with or without imaging abnormalities (12). Cipolli et al reported in their study cohort that elevated ALT, GGT, or ALP of 2 or more occasions before age 6.5 were linked to a higher risk of PHT. Elevated ALT had a hazard ratio of 2.7 but only had a sensitivity of ~20% and PPV of 10%–20% (13). Overall, there is insufficient evidence to suggest that changes in ALT and/or AST levels over time can reliably predict the development of structural hepatic abnormalities in pwCF. However, when transaminases remain

TABLE 2. Schematic classification of cystic fibrosis hepato-biliary involvement (CFHBI)* in people with CF

Elevation of liver enzymes (> 1.5× ULN†)		
E0	No elevation of liver enzymes	Either AST/ALT/GGT
E1	Transient elevation of liver enzymes	
E2	Persistent elevation of liver enzymes >6 months	
Imaging of the liver		
Either ultrasound/MRI		
I0	No imaging abnormalities	
I1	Heterogeneous increased signal	
I2	Nodular imaging abnormalities	
I3	Homogeneous increased signal	
In	No imaging available	
Histopathology of the liver		
H0	No histopathological abnormalities	
H1	a Fibrosis F1–F2	METAVIR classification
	b Fibrosis F3–F4	
H2	Obliterative portal venopathy	
H3	Steatosis	
H4	Cholestatic histopathology	
Hn	No histology available	
Stiffness of the liver		
Various modalities of elastography		
S0	Normal liver stiffness	
S1	Increased liver stiffness	
Sn	Liver stiffness was not measured	
Portal hypertension‡		
PO	No portal hypertension	
P1	Cirrhotic portal hypertension	- Histology consistent with cirrhosis (F4) AND/OR - Severe increase of liver stiffness (see Table 3A, Supplemental Digital Content 1, http://links.lww.com/MPG/D344 for cutoff values)
P2	Non cirrhotic portal hypertension	<i>Supportive cirrhosis: macronodular liver including an irregular edge, inhomogeneous parenchyma on imaging</i> - Histology not consistent with fibrosis or cirrhosis <i>Supportive of non-cirrhotic: normal or mildly elevated HVPG and/or no macronodular appearance of the liver on imaging</i>
Biliary manifestations		
B0	No biliary involvement	
B1	Cholelithiasis and hepatolithiasis	
B2	Biliary strictures	MRCP or ERCP
Malignancies of the liver and biliary tract		
M0	No malignancies	
M1	Hepatocellular carcinoma	
M2	Cholangiocarcinoma	

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ERCP = endoscopic retrograde cholangiopancreatography; GGT = gamma-glutamyl transpeptidase; HVPG = hepatic venous pressure gradient; MRCP = magnetic resonance cholangiopancreatography; MRI = magnetic resonance imaging; ULN = upper limit of normal. * Ranking in numbering and lettering are used for classification and do not represent hierarchy in severity. † ULN cutoff value of 1.5 times the normal range to avoid misclassifying, particularly those with borderline results. ‡ Portal hypertension is defined by any 1 of the following criteria: 1. Persistent splenomegaly either by physical exam or by imaging; 2. Persistent hypersplenism (platelet count <150 × 10⁹/L); 3. Esophageal or gastric varices or portal hypertensive gastropathy; 4. Hepatic venous pressure gradient >10 mm Hg.

persistently elevated in pwCF, it is necessary to consider a broader range of differential diagnoses.

GGT

GGT is expressed in high concentration in cholangiocytes and an increase in serum GGT concentration may

indicate bile duct or cholangiocyte damage, such as in the case of bile duct obstruction or other cholangiopathies. In children with CF, sustained elevation of GGT, defined as values above 30 IU/L, have been associated with the occurrence or presence of structural nodular liver transformation and cirrhosis (2,12,14).

Gamma-glutamyl transpeptidase-to-platelet ratio (GPR)

$$\text{GPR} = \frac{\text{GGT [U/L]}/\text{upper limit of normal GGT [U/L]} \times 100}{\text{Platelet count [10}^9\text{/L]}}$$

GPR is reported as a potentially valuable diagnostic tool in fibrosis liver disease (15). Calvopina et al showed elevated levels of GPR indicate liver damage in pediatric pwCF, with good diagnostic accuracy for detecting hepatic fibrosis severity and predicting the presence of PHT. These findings suggest that GPR can aid in better identification of patients at risk for PHT and timely follow-up and treatment (16).

AST to platelet index (APRI) score

The APRI, or APRI score, has been validated for the determination of the likelihood of hepatic fibrosis and cirrhosis in hepatitis C (17,18).

$$\text{APRI} = \frac{\text{AST [U/L]}/\text{upper limit of normal AST [U/L]} \times 100}{\text{Platelet count [10}^9\text{/L]}}$$

Leung et al (19) reported in a retrospective, cross-sectional, biopsy-validated study in pediatric pwCF with suspected liver disease, defined by the Debray criteria, that a 50% increase in APRI score was associated with a 2.3-fold risk of having severe fibrosis. APRI scores above a cutoff of 0.462 were a significant indicator of severe fibrosis. However, in their study APRI overestimated the fibrosis stage in almost half of the cases and underestimated fibrosis in almost 20% (19). In a recent study by Ling et al (12), it was found that the APRI was approximately 2-fold higher in individuals with a nodular liver on US than in those with a normal US pattern. It should be noted that the APRI values for advanced fibrosis in pwCF are much lower than those described for viral hepatitis.

FIB-4 Score

$$\text{FIB-4 Score} = \frac{\text{Age [years]} \times \text{AST [U/L]}}{\text{Platelet count [10}^9\text{/L]} \times (\sqrt{\text{ALT [U/L]}})}$$

FIB-4 score was developed as a noninvasive biomarker to assess the severity of liver fibrosis in hepatitis C, with the aim to replace liver biopsy (20). FIB-4 has subsequently been validated as biomarker for fibrosis and cirrhosis in hepatitis B and NAFLD (nonalcoholic fatty liver disease) (21,22). In general, a low FIB-4 score excludes the presence of liver fibrosis, whereas a high score increases the likelihood of advanced liver fibrosis. Cutoff values of FIB-4 scores are available for different age categories, but the scores are not well validated for individuals under 35 years of age. FIB-4 has been studied in children with NAFLD where, compared to histopathology, it did not accurately predict any significant or advanced fibrosis (23). Leung et al reported that, in children with CF, FIB-4 was significantly lower in the no-CFLD group than in the CFLD group when compared between the groups. However, in this study, FIB-4 had a lower accuracy to predict liver fibrosis than APRI when compared to liver histology (19).

Position Statements Regarding Elevation of Liver Enzymes in pwCF

1. Elevations of transaminase (AST and ALT) are a common and frequent manifestation of CFHBI in pwCF.
2. Elevation of transaminases (AST and ALT) is neither sensitive nor a specific marker for variants of CFHBI in pwCF.

3. Persistent elevation of transaminases (AST and ALT) should warrant a broader diagnostic approach to the underlying cause.
4. GGT, GRP, APRI, and FIB-4 are useful for detecting advanced fibrotic liver disease and cirrhosis with PHT and are less discriminative for milder forms of fibrotic liver involvement.

Recommended CFHBI Classification* for Elevation of Liver Enzymes (E)

- E0 No elevation of liver enzymes
 - E1 Transient elevation of liver enzymes
 - E2 Persistent elevation of liver enzymes (> 6 months)
- *Please refer to Table 2 for more information.

HEPATIC IMAGING (I)

Liver imaging is a noninvasive method for obtaining information about the overall appearance of the parenchyma and any structural changes in the parenchyma and/or biliary system. Over time, imaging in pwCF has transitioned from a targeted diagnostic tool used to identify cirrhotic morphology to a screening instrument employed for routine follow-up (1). Although this has led to a more comprehensive imaging depiction of CFHBI, the challenge remains in consistently categorizing imaging observations and determining the progression and prognosis of liver disease.

Ultrasonography of the Liver

Ultrasound has been the most widely used and studied imaging method for the liver in pwCF. The liver US classification for pwCF proposed in 1995 by Williams et al (24) has become widespread and involves a classification of liver US findings into:

1. Normal
2. Heterogeneous increased echogenicity
3. Homogeneous increased echogenicity
4. Nodularity of the liver.

The assessment of ultrasonographic findings related to liver echogenicity, such as homogeneous or heterogeneous increases, can be influenced by interobserver variability. A heterogeneous pattern on US can be a potential indicator of fibrosis, but it can also be caused by patchy steatosis (8). Additionally, a heterogeneous US pattern of the liver has been suggested to indicate patients at risk for cirrhosis (25–27), and could potentially be used as a clinical outcome measure.

Use of US has not been recommended universally for routine screening but is recommended if there is a suspicion for liver involvement based on clinical exam or biochemical indices (8,28). Sellers et al (29) demonstrated that targeted use of US based on indices of fibrosis can increase the detection of advanced liver disease in children with CF.

The finding of a nodular liver on US has good specificity for structural liver disease in adults with CF (30). However, a nodular US liver pattern may not discriminate between cirrhotic or non-cirrhotic disease of the liver (31,32). Patients with a heterogeneous pattern of the liver on US had a 5.2-fold increased incidence of cirrhosis and a 6.1-fold increased incidence of PHT compared to children with a normal pattern on liver US (25). A longitudinal study of the use of liver US to predict the development of advanced liver disease has confirmed that a heterogeneous pattern of the liver on US as determined by the consensus of 3 study radiologists is associated with a significant, 9-fold, increased risk for development of a nodular liver compared to children who had a normal US pattern at entry to the study (27).

Computed Tomography (CT) Imaging of the Liver

Abdominal CT imaging has been utilized to assess liver architecture and can differentiate fibrosis and steatosis more accurately than US (33). However, in pwCF, its use is restricted to reduce radiation exposure, and it frequently is being replaced by magnetic resonance imaging (MRI).

MRI of the Liver

MRI of the liver is well suited to evaluate structural abnormalities of the liver and is the imaging modality of choice for focal lesions of the liver. Furthermore, MRI can discriminate between fat and fibrosis. Quantifying liver proton density fat fraction (PDFF) using IDEAL-IQ sequence PDFF, or other evolving methods may enable the grading of steatosis (34–36). However, the need for sedation has limited the use of liver MRI in younger pwCF. In adults with CF, a short unenhanced MRI protocol can identify 3 key features: altered gallbladder morphology, periportal tracking, and periportal fat deposition (37). With the advancements in MRI techniques, the evaluation of CFHBI in pwCF could potentially benefit from this modality.

Position Statements Regarding Imaging of the Liver in pwCF

1. Liver US is currently the most frequently used and advised imaging method for characterizing the liver in pwCF.
2. A normal US result correlates well with absence of structural CFHBI at the time of examination.
3. Nodular parenchymal pattern on liver US, CT, or MRI has good specificity for the presence of structural CFHBI including cirrhosis and nodular regenerative hyperplasia (NRH).
4. A liver US showing a heterogeneous increased echogenicity pattern suggests an elevated risk of advanced CFHBI.
5. The clinical and prognostic importance of a homogeneous increased pattern of the liver on US suggestive for steatosis is uncertain.
6. The additional significance and applicability of CT scanning of the liver in CFHBI is limited.
7. Although the role of MRI in CFHBI shows promise, its precise indication and benefit in standard clinical practice and follow up of pwCF are yet to be determined.

Recommended CFHBI Classification* for Imaging of the Liver (I)

- I0 No imaging abnormalities
- I1 Heterogeneous increased signal
- I2 Nodular imaging abnormalities
- I3 Homogenous increased signal
- In No imaging available

*Please refer to Table 2 for more information.

HEPATIC HISTOPATHOLOGY (H)

Liver histology in pwCF can be obtained through liver biopsy, hepatectomy (eg, in case of liver transplantation), or postmortem studies. While liver biopsy is regarded as the gold standard for diagnosing and categorizing liver disease, it is not commonly used in CF care. Arguments used to refrain from liver biopsy are the limited clinical and therapeutic consequences of

the histological results and potential increased procedural risks due to pulmonary hyperinflation. In pwCF, histological abnormalities can be focally distributed in the liver, introducing the risk of sampling error of a liver biopsy. Despite the known limitations, dual-pass biopsy has been advocated by some as the preferred modality in the evaluation of hepatic histopathology in pwCF (38). Common indications for liver biopsy in pwCF may include:

1. Need for differentiation between cirrhotic and non-cirrhotic liver disease (31).
2. Evaluation for other (potentially treatable) causes of liver disease such as autoimmune hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, alpha-1 antitrypsin deficiency (39,40), Wilson disease (41), drug-induced liver disease (42), and others.
3. Evaluation of liver-lung transplantation candidates regarding clinical consequences and therapeutic options.

CF has been associated with 4 primary hepatic histopathologic patterns:

1. Preponderant fibrotic and cirrhotic features including
 - a. Multilobular cirrhosis
 - b. Focal biliary cirrhosis
 - c. Portal or cholangial inflammation with fibrosis
2. Obliterative portal venopathy
3. Steatosis with or without inflammation or fibrosis
4. (Neonatal) cholestatic features

Cholestatic histopathology is reported in neonates and infants, the other histopathologic patterns are typically identified during later childhood and adulthood.

Fibrosis and Cirrhosis (H1)

Biliary cirrhosis has long been described as a typical pathology of liver involvement in pwCF. A distinction has been made between “focal biliary cirrhosis” and “multilobular (biliary) cirrhosis,” the latter associated with cirrhotic PHT. The most-reported fibrotic hepatic histopathological findings in older children with CF are various degrees of portal fibrosis, bile duct proliferation, cholangitis, peri-cholangitis, and portal inflammatory infiltration (mainly neutrophils), as well as ductular inspissation of mucus, often with eosinophilic material (43–45). Several authors observed that ductular proliferation and inflammatory cells were more prominent in younger patients (44,46,47). To histologically assess fibrosis in CFLD, the METAVIR scoring system is most frequently utilized and reported, which was initially developed to evaluate fibrosis in viral hepatitis (16,38).

Obliterative Portal Venopathy (H2)

As an alternative to the biliary obstructive theory, other studies have reported findings to support the concept that liver injury is related to alterations in gut-liver axis (48) and/or to vasculopathy (31,32). In a study by Witters et al, 12 pwCF and PHT underwent liver biopsy or examination of the liver explant. In 7 participants, the liver samples showed no evidence of cirrhosis, but the absence of portal vein branches in over 40% of portal tracts, consistent with non-cirrhotic (presinusoidal) PHT (31). Subsequently, the same group reported a small case series with comparable outcomes (49). Hillaire et al (50) confirmed these findings by identifying non-cirrhotic (presinusoidal) PHT caused by obliterative portal venopathy with nodular regeneration in explants obtained from 8 out of 10 adult liver transplant recipients with CF. A global panel of experts has proposed discontinuing the use of the term “obliterative portal

venopathy” and replacing it with “porto-sinusoidal vascular disease (PSVD)” (51).

Steatosis (H3)

Although mild to moderate macro-vesicular steatosis is a common finding in pwCF, its underlying pathophysiology is not well understood. Steatosis has been related to malnutrition (53,54) or, more specifically, to essential fatty acid deficiency (55), but other, yet undiscovered factors may be involved, as steatosis is also observed in children with good nutritional status (56). It was suggested more than 50 years ago (45), that malnutrition is likely not the only cause of hepatic steatosis in pwCF and that other factors (such as intercurrent illness, choice of supplemental nutrition, and the underlying disease itself) could play a role. Although there are reports of pwCF in whom steatosis rapidly progressed to fibrosis and cirrhosis (45), the significance of steatosis as a potential risk factor for more severe forms of CFHBI, including cirrhosis, is not known.

(Neonatal) Cholestatic Features (H4)

Neonates or infants with CF may present with persistent neonatal jaundice based on conjugated (direct) hyperbilirubinemia. Liver histology in neonates and infants with CF shows broadened portal tracts, portal fibrosis, ductular proliferation, and inspissated granular eosinophilic material in bile ducts (39). Some authors describe paucity of interlobular bile ducts in neonatal cholestasis associated with CF (57). Only very few cases of cholestasis were described in these cohorts, and those were primarily the youngest children with meconium ileus (39).

Position Statements Regarding Histopathology of the Liver in pwCF

- There are 4 major hepatic histopathological variants recognized in pwCF:
 - Preponderant fibrotic and cirrhotic features
 - Multilobular cirrhosis
 - Focal biliary cirrhosis
 - Portal or cholangial inflammation with fibrosis
 - Obliterative portal venopathy
 - Steatosis
 - (Neonatal) cholestatic features
- Liver fibrosis in pwCF should be assessed using the METAVIR scoring system

Recommended CFHBI Classification* for Histopathology of the Liver (H)

- H0 No histopathological abnormalities
- H1a Fibrosis F1–F2
- H1b Fibrosis F3–F4
- H2 Obliterative portal venopathy
- H3 Steatosis
- H4 Cholestatic histopathology
- Hn No histology available

*Please refer to Table 2 for more information.

LIVER STIFFNESS (S)

LSM are used to determine the elastic properties of the liver. An increase in liver stiffness is a noninvasive surrogate sign of a fibrotic change of the liver parenchyma. Liver stiffness is reported as a continuous quantitative variable and is used to estimate hepatic fibrosis stage or change of fibrosis over time.

Multiple modalities including vibration controlled transient elastography (VCTE), US elastography [acoustic radiation force

impulse (ARFI)], or 2D shear wave elastography (SWE) and magnetic resonance elastography (MRE) are used. Due to variations in technology and algorithms used, inter-modality comparisons cannot be made on a 1:1 basis and, accordingly, cutoff values are modality specific (58). Below, we summarize the experience of the various available modalities for LSM in pwCF.

VCTE

The first study to evaluate the use of VCTE in pwCF was performed in 2009 (59). Since that time, several studies have reported on the utility of VCTE to identify liver disease and liver disease progression in pwCF. However, the collective experience with VCTE is complicated by inconsistent definitions of CFLD. This has resulted in a wide range of cutoff values (reported cutoff values summarized in Table 3, Supplemental Digital Content 1, <http://links.lww.com/MPG/D344>). Proposed cutoff values for advanced CFLD with PHT vary from 6.2 to 22.5 kPa with varying sensitivity and specificity (Table 4, Supplemental Digital Content 2, <http://links.lww.com/MPG/D345>). Although VCTE samples a far larger portion of the liver than biopsy, it still only samples ~1% of the liver and sampling error may occur given the described patchy nature of liver involvement in pwCF (10). In pwCF who have severe, restrictive lung disease, right-sided cardiac dysfunction, or elevated hepatic inflammation, LSM are elevated and may not indicate to hepatic fibrosis. Therefore, it is important to interpret these results within the context of the individual’s overall medical status and disease condition.

ARFI Elastography

ARFI utilizes radiation-forced impulses to determine LSM during routine US examination. Among 9 studies of ARFI in pwCF since 2011 (60–68), a similar experience to VCTE was noted, with varying definitions for CFLD degrees of severity used and a wide range of LSM values between groups (reported cutoff values summarized in Table 3, Supplemental Digital Content 1, <http://links.lww.com/MPG/D344>). Only 2 studies proposed cutoff values for the presence of CFLD ranging from 1.28 to 1.45 m/s (mild differences between left and right lobes), and only 1 study proposed a cutoff for advanced CFLD at 1.3 m/s. ARFI does not appear to have a unique advantage or disadvantage compared to VCTE in the evaluation of LSM in pwCF. Given the significant overlap, ARFI does not appear to be sufficiently reliable in determining the severity of CFHBI and is unlikely to be of benefit in following progression of disease severity over time.

2D SWE

Like ARFI, SWE has the benefit of being obtained with routine B-mode US. It is suggested that SWE may be better at detecting incremental changes in liver disease among children. In a single center study of 125 children (29 controls, 41 pwCF without liver disease, and 55 with CFLD based on the Debray criteria (8)), using SWE, the median LSM was significantly higher among individuals with CFLD (8.1 kPa, 6.7–11.9) compared to pwCF without liver disease (6.2 kPa, 5.6–7.0; $P < 0.001$) and controls (5.3 kPa, 4.9–5.8; $P < 0.001$) (69). The authors proposed a cutoff of 6.85 kPa which had a sensitivity and specificity of 75% and 71%, respectively, in detecting CFLD. Further evaluation of SWE in pwCF is required to determine to what extent this methodology would be of benefit in following progression of disease severity over time.

MRE

MRE utilizes a mechanical wave from a passive driver secured to the patient’s chest to indirectly both regional and global LSM (70). A stiffness heat map is then generated through

post-processing to provide a global visual assessment of liver stiffness. Although MRI sequences are getting faster, children unable to stay still throughout the study may need sedation. Normal ranges for children without liver disease have been reported (71). The experience of MRE in pwCF is limited to single-center studies (72,73). There is insufficient data to determine if MRE has improved diagnostic performance compared to TE (transient elastography) or SWE. MRE has the advantage to globally assess liver stiffness. Still, experience is limited in pwCF and MRE may lack broader clinical utility due to cost and the potential need for sedation in young children.

There are several studies where imaging findings are combined with serum markers to better delineate severity of liver involvement in pwCF (12,27,29,63,74,75). Further evaluation is needed to determine if combining modalities to assess fibrosis improves sensitivity and specificity.

Controlled Attenuation Parameter (CAP)

The CAP is a noninvasive technique used to measure the fat in the liver. It is a component of TE, an US-based diagnostic tool used to assess liver stiffness as an indirect measure of liver fibrosis. In a report by Bader et al (76) evaluating CAP in pwCF aged 6–25 years, there was no difference in CAP observed between subjects with no CFLD and those with CFLD and PHT. Although CAP appeared to be correlated with US findings in pwCF, it was not related to other markers of liver disease and was normal in most patients. Recently Ye et al reported on the relation between CAP and US findings in pwCF. They found CAP levels differed significantly among groups including normal, heterogeneous, homogeneously hyperechoic, and nodular liver US findings. The homogeneous hyperechoic liver US group had a significantly higher mean CAP than all the other 3 groups (77). As more studies evaluate CAP in pwCF, this modality may become more important in the diagnosis of steatosis in pwCF, as well as determining the clinical implications of steatosis in pwCF.

Position Statements Regarding Liver Stiffness in pwCF

1. Increased liver stiffness is a diagnostic indicator of CFHBI in pwCF.
2. Measuring liver stiffness can be used as a surrogate quantitative measurement to grade the degree of liver fibrosis in pwCF. Multiple modalities for measuring liver stiffness are available.
3. High liver stiffness values obtained by VCTE, after taking into consideration other cause of increased liver stiffness, likely indicate the presence of severe fibrotic or cirrhotic variants of CFHBI in pwCF, but the optimal cutoff values have yet to be established.
4. Recent technologies such as 2D SWE and MRE may offer new strategies in detecting incremental changes in liver stiffness in pwCF but need further evaluation and validation.
5. With more studies investigating CAP in pwCF, this method may in the future gain significance in diagnosing steatosis in pwCF and determining the clinical implications of steatosis in pwCF.

Recommended CFHBI Classification* for Stiffness of the Liver (S)

- S0 Normal liver stiffness
- S1 Increased liver stiffness
- Sn Liver stiffness was not measured

*Please refer to Table 2 for more information.

PHT (P)

PHT is the most clinically significant and severe manifestation of CFHBI. The development of PHT is associated with increased morbidity and mortality (78,79). While present in only 3%–10% of pwCF, advanced liver disease with PHT is the 3rd leading cause of mortality in pwCF (3,80,81).

In pwCF, there are 2 distinct described pathophysiological etiologies for PHT, including a cirrhotic and a non-cirrhotic variant.

Cirrhotic PHT (P1)

Cirrhosis is histologically characterized by progressive biliary fibrosis. Cirrhosis is the most prevalent cause of PHT in pwCF and typically develops in children and adolescents with classic multinodular cirrhosis (56,82).

Non-cirrhotic PHT (P2)

Non cirrhotic PHT is thought to be related to CF-related hepatic venopathy and is described more commonly later in adulthood (9,31,49,50). In non-cirrhotic PHT, histopathology shows signs of obliterative portal venopathy and NRH (32,49,50).

The treatments for PHT in pwCF focus on preventing and managing complications that result from gastrointestinal variceal bleeding and include variceal band ligation (78), portosystemic shunt procedures (83), and liver transplantation (84,85).

Assessment of the Presence of PHT

Splenomegaly

Often, the initial and most common sign of PHT in pwCF is splenomegaly (3), identified by either physical exam or imaging. The use of imaging to assess splenomegaly in pwCF is preferred because thoracic hyperinflation, which can be found in pwCF, may lead to a more readily palpable spleen. For assessment of splenomegaly with imaging modalities, there are specific cutoff values of the spleen span for adults and children. In adults, the ULN spleen span on imaging is ~14 cm (86). In children, a measured spleen span greater than 2 SD is regarded as enlarged (87,88)

Thrombocytopenia

Splenomegaly is often accompanied, or followed by, signs of hypersplenism such as a progressive decrease in the platelet count. Thrombocytopenia is strongly associated with PHT in pwCF (89). In addition, a steady decrease in platelet count over time is regarded as a relevant sign of development/progression of PHT. It is also important to consider that platelet count may vary as part of an acute phase response related to inflammatory processes and infections. Therefore, it is advised to monitor the platelet count over longer periods of time. Although clinically clearly recognizable, there is currently no standardized threshold value for either platelet count or the rate of platelet decline that can be used to diagnose PHT.

Spleen Stiffness Measurement

Another noninvasive diagnostic modality for PHT is spleen stiffness measurement. Although promising in both adults and children with PHT, spleen stiffness measurement is not widely available and still requires validation for pwCF with PHT (90,91).

Gastrointestinal Varices and Variceal Bleeding

Confirmation of PHT can be made through endoscopic diagnosis of gastrointestinal varices or documented episodes of gastrointestinal variceal bleeding. While varices and variceal bleeding are frequently observed in the esophagus and stomach cardia, they can also emerge in other regions of the gastrointestinal tract.

Direct and Indirect Portal Vein Pressure Measurements

Direct invasive measurement in the portal vein provides the most precise quantification of portal venous pressure. However, introducing a catheter directly into the portal vein is a complex procedure. A less hazardous invasive technique involves catheter placement in the hepatic vein to measure the hepatic venous pressure gradient (HVPG). In adults with cirrhosis, HVPG ≥ 10 mmHg is diagnostic of clinically significant PHT that has been associated with the presence of esophageal varices (92,93). In pediatric liver disease, direct or indirect measurements of portal pressure are rarely performed. No specific pediatric cutoff values have been established; therefore, the adult criteria are applied (94). It is worth noting that both obliterative portal venopathy and NRH, significant causes of PHT in pwCF, are presinusoidal lesions. Even with a normal or minimally elevated HVPG, clinically significant PHT may still be present. In pwCF, invasive portal vein pressure measurements can be considered in the evaluation for liver and/or lung transplantation to assess the severity of the PHT.

Additional Complications of Cirrhosis and PHT in pwCF

Although additional signs of liver failure and secondary complications of cirrhosis and PHT, such as ascites, jaundice, spider nevi, erythema palmaris, clubbing, caput medusae, and hypoxemia in case of hepatopulmonary syndrome, may be observed in pwCF, they are not explicitly discussed as part of the current classification of CFHBI.

Position Statements Regarding PHT in pwCF

1. Liver involvement presenting with PHT is the most clinically significant manifestation of CFHBI associated with increased morbidity and mortality.
2. The committee advises classifying CFHBI with PHT as either cirrhotic or non-cirrhotic.
3. There are 4 distinct signs indicative for PHT in pwCF:
 - a. Splenomegaly determined by either physical examination or preferably by imaging.
 - b. Persistent thrombocytopenia and/or decline of platelet count*.
 - c. Gastrointestinal varices and/or variceal bleeding.
 - d. Increased HVPG*.

*Uniform cutoffs have yet to be determined.

Recommended CFHBI Classification* for PHT (P)

- P0 No PHT
- P1 Cirrhotic PHT
- P2 Non cirrhotic PHT

*Please refer to Table 2 for more information.

BILIARY MANIFESTATIONS (B)

PwCF can exhibit cholangiopathy and other bile duct-related abnormalities as part of CF-related hepatobiliary disease (CFHBI). Multiple theories have been proposed regarding the underlying cause of cholangiopathies in pwCF. In the liver, CFTR is solely present at the apical membrane of cholangiocytes that line the bile ducts and gallbladder. Consequently, local dysfunction of CFTR protein could lead to changes in bile composition, such as alterations in bile acid concentration and pH, resulting in cholangiocyte injury or precipitation of bile salts. Other theories about cholangiopathies include dysregulation of the liver-gut axis, such as variations in gut-liver signaling, intestinal inflammation, and microbial

factors (48,95). As with other forms of CFHBI, it is not clear if cholangiopathies represent a distinct pathophysiological mechanism or a continuous and interrelated spectrum of the hepatobiliary disease in pwCF.

Gallstones (B1)

Gallstones are common in pwCF, presenting primarily as cholelithiasis but may also present as intrahepatic hepatolithiasis (96). Asymptomatic gallstones have been reported in approximately 5% of routine yearly US in pwCF (97). Gallstones requiring intervention were reported in only 0.2% of the CF population in the United States CF Foundation patient registry (3). However, others have reported symptomatic gallstones in up to 4% of pwCF (98).

Biliary Strictures (B2)

PwCF can develop strictures in both intrahepatic and extrahepatic bile ducts. Strictures in pwCF can be identified through ultrasonography, magnetic resonance cholangiopancreatography (MRCP), or endoscopic retrograde cholangiopancreatography. Radiological findings on a cholangiogram may bear resemblance to cholangiopathies observed in primary sclerosing cholangitis or autoimmune conditions. In the past, imaging studies showed that bile duct strictures were a common occurrence in pwCF; however, significant biliary obstruction and septic cholangitis are rare clinical occurrences (99–101).

Recommended CFHBI Classification* for Biliary Manifestations (B)

- B0 No biliary involvement
- B1 Cholelithiasis and hepatolithiasis
- B2 Biliary strictures

*Please refer to Table 2 for more information.

Malignancies of Liver and Biliary Tract (M)

Hepatocellular Carcinoma (M1)

Hepatocellular disease and cirrhosis are established risk factors for the onset of hepatocellular carcinoma (HCC) in the general population. Although the incidence of HCC is notably low in pwCF, its likelihood of occurrence is greater in comparison to the general population (102). HCC in pwCF can develop in (young) adults (2nd–4th decade of life) with known CF-related cirrhosis (103–106). With increased survival, the cumulative risk of developing HCC in pwCF with cirrhosis may increase. Thus far, HCC has not been reported in non-cirrhotic CF liver involvement. As in other forms of liver cancer, a high alpha-fetoprotein might suggest the presence of HCC, but normal levels do not exclude it. Specific screening protocols for HCC in pwCF are limited, mainly due to the fact that US and MRI criteria used to identify HCC may be less reliable in pwCF (106).

Cholangiocarcinoma (M2)

Compared to the general population, the risk of developing biliary tract cancer is more significant in pwCF (pooled standardized incidence ratio [95% CI] 17.9 [8.6–37.4; $P < 0.0001$] for biliary tract cancer) (102,107). The risk is even higher in pwCF after lung transplantation (108). Screening protocols, including US, MRCP, and measurement of cancer antigen 19-9 (CA 19-9) has been proposed every 2–3 years. However, these recommendations have yet to be validated.

Recommended CFHBI Classification* for Malignancies of the Liver and Biliary Tract (M)

- M0 No malignant manifestations
- M1 Hepatocellular carcinoma
- M2 Cholangiocarcinoma

*Please refer to Table 2 for more information.

SUMMARY AND RECOMMENDATIONS

Liver and biliary involvement is common in pwCF. Currently, most described clinical hepatic and biliary presentations are grouped under the term “CF liver disease (CFLD).” To improve understanding and research of CF-related hepatobiliary involvement in pwCF, we suggest replacing the term CFLD with CF hepatobiliary involvement (CFHBI).

The Classification of CFHBI is an Ongoing and Evolving Process

CFHBI presenting as an advanced liver disease with PHT represents the most critical form of CFHBI in terms of morbidity and mortality. Individuals with this manifestation are at greater risk of liver failure, requiring liver transplantation, and experiencing elevated overall mortality rates. The implications of other manifestations of CFHBI, such as those identified by liver biochemistry liver imaging, liver histology, or elevated liver stiffness, on morbidity and mortality, as well as disease progression, are more uncertain. Our current description of CFHBI mirrors the existing clinical practice and scientific understanding of liver involvement in pwCF. As novel diagnostic techniques and therapeutic alternatives emerge, revising and augmenting the current proposal may become necessary.

Role for the Classification of CFHBI Manifestations for Describing Natural History

The natural history of the various CFHBI manifestations and their mutual pathophysiological relationship are unknown. It is well recognized that the peak age of the diagnosis of cirrhosis in pwCF is around the age of 10 years (7,89). However, the preliminary stages of hepatic disease in these patients have not been clearly identified, leading to challenges in identifying patients at risk. Recent data suggests a consensus determination of heterogeneous US patterns of the liver identifies individuals with an increased risk for severe liver involvement, including PHT. However, a slight majority of those with a heterogeneous pattern will not develop PHT (26,27). Another example is steatosis: it is a well-described radiological and histological entity in pwCF, but it is unknown if steatosis or its ultrasonographic correlation, a homogeneously echogenic liver, plays any role in the development or progression of CFHBI manifestations.

Role for Classification for the CFHBI Manifestations in the Clinic, Registries, and Clinical Research

Using a systematic classification system for CFHBI manifestations provides a role in clinical care, patient registries, and clinical research. A more detailed categorization of CFHBI allows for improved recognition and monitoring of liver disease progression in pwCF. The proposed classification can also provide uniformity in patient registries and inclusion criteria for clinical trials. This approach can improve our understanding of CFHBI manifestations and advance treatment for CF in general like CFTR modulators and CFHBI-specific treatments.

Table 2 displays our recommended classification system for cystic fibrosis-related hepatobiliary (CFHBI) manifestations. It includes descriptive and diagnostic criteria for each of 7 lettered categories of CFHBI:

- E Elevation of liver enzymes
- I Imaging findings of the liver
- H Histopathology of the liver
- S Stiffness of the liver
- P Portal hypertension

B Biliary manifestations

M Malignancies of the liver or biliary tract

The defined CFHBI categories each have numbered sub-headings to describe the specific representations precisely. The ranking in numbering and letter are used for classification and do not represent a hierarchy in severity. This classification allows for pwCF to be precisely categorized based on their CFHBI-related presentation. For instance, a patient with elevated isolated liver enzymes would be recorded as CFHBI: E1, while someone with non-cirrhotic PHT and increased liver stiffness would be classified as CFHBI: S1/P2. Consistent application of the new classification will benefit the CF community and enhance our understanding and treatment of liver and biliary involvement in pwCF. The current position paper is not intended to be used as a guideline. Regarding the subject of imaging in pwCF, for example, we do not advise performing MRI scans of the liver for all patients. However, if an MRI is performed and an irregular nodular liver is observed, we would suggest using this information to classify this person with CF as: I2 Nodular imaging abnormalities.

In this joint ESPGHAN-NASPGHAN position paper, we have recommended a classification system for CFHBI, based on expert consensus, that health care providers can incorporate into their clinical practice when assessing and diagnosing liver and biliary involvement in pwCF. This classification system more accurately defines CFHBI presentations and allows for a more precise categorization of patients based on their specific CFHBI signs. Consistent use of this classification system can enhance our understanding and management of CFHBI and may benefit the pwCF and the CF community. The recommended CFHBI classification has yet to be validated for use in clinical practice and research, a key objective in future studies.

REFERENCES

- Debray D, Narkewicz MR, Bodewes F, et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. *J Pediatr Gastroenterol Nutr* 2017;65:443–8.
- Woodruff SA, Sontag MK, Accurso F, Sokol RJ, Narkewicz MR. Prevalence of elevated liver function tests in children with cystic fibrosis diagnosed by newborn screen. *J Pediatr Gastroenterol Nutr* 2007;45:E27–8.
- Cystic Fibrosis Foundation. *Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report*. Bethesda, MD: Cystic Fibrosis Foundation; 2022.
- Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. *Cochrane Database Syst Rev* 2017;2021:CD000222.
- Boelle PY, Debray D, Guillot L, Clement A, Corvol H, French CF Modifier Gene Study Investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. *Hepatology* 2019;69:1648–56.
- Colombo C, Alicandro G, Oliver M, et al. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study. *J Cyst Fibros* 2022;21:220–6.
- Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. *Hepatology* 2002;36:1374–82.
- Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. *J Cyst Fibros* 2011;10:S29–36.
- Koh C, Sakiani S, Surana P, et al. Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity. *Hepatology* 2017;66:591–601.
- Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. *J Cyst Fibros* 2013;12:116–24.
- Patriquin H, Lenaerts C, Smith L, et al. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. *Radiology* 1999;211:229–32. Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10189476.

12. Ling SC, Ye W, Leung DH, et al. Liver ultrasound patterns in children with cystic fibrosis correlate with non-invasive tests of liver disease. *J Pediatr Gastroenterol Nutr* 2019;69:351–7.
13. Cipolli M, Fethney J, Waters D, et al. Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: a longitudinal prospective birth cohort study. *J Cyst Fibros* 2020;19:455–9.
14. Bodewes FA, van der Doef HP, Houwen RH, Verkade HJ. Increase of serum gamma-glutamyltransferase associated with development of cirrhotic cystic fibrosis liver disease. *J Pediatr Gastroenterol Nutr* 2015;61:113–8.
15. Li Q, Lu C, Li W, Huang Y, Chen L. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease. *Oncotarget* 2017;8:28641–9.
16. Calvopina DA, Lewindon PJ, Ramm LE, et al. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric cystic fibrosis. *J Cyst Fibros* 2022;21:236–42.
17. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology* 2011;53:726–36.
18. Wai CT, Greenon JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38:518–26.
19. Leung DH, Khan M, Minard CG, et al. Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease. *Hepatology* 2015;62:1576–83.
20. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006;43:1317–25.
21. Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. *Liver Int* 2010;30:546–53.
22. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Am J Gastroenterol* 2017;112:740–51.
23. Mansoor S, Yerian L, Kohli R, et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. *Dig Dis Sci* 2015;60:1440–7.
24. Williams SG, Evanson JE, Barrett N, Hodson ME, Boulton JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. *J Hepatol* 1995;22:513–21.
25. Lenaerts C, Lapierre C, Patriquin H, et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. *J Pediatr* 2003;143:343–50.
26. Siegel MJ, Freeman AJ, Ye W, et al. Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease: interim results of a prospective observational case-controlled study. *J Pediatr* 2020;219:62–9.e4.
27. Siegel MJ, Leung DH, Molleston JP, et al. Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease. *J Cyst Fibros* 2023;22:745–55.
28. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. *J Pediatr Gastroenterol Nutr* 1999;28(suppl 1):S1–13 (in English). Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9934970.
29. Sellers ZM, Lee LW, Barth RA, Milla C. New algorithm for the integration of ultrasound into cystic fibrosis liver disease screening. *J Pediatr Gastroenterol Nutr* 2019;69:404–10.
30. Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. *J Cyst Fibros* 2008;7:215–21.
31. Witters P, Libbrecht L, Roskams T, et al. Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. *Hepatology* 2011;53:1064–5.
32. Wu H, Vu M, Dhingra S, et al. Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. *Clin Gastroenterol Hepatol* 2019;17:2134–6.
33. Akata D, Akhan O, Ozcelik U, et al. Hepatobiliary manifestations of cystic fibrosis in children: correlation of CT and US findings. *Eur J Radiol* 2002;41:26–33.
34. Kutney K, Donnola SB, Flask CA, et al. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. *World J Hepatol* 2019;11:761–72.
35. Runge JH, Smits LP, Verheij J, et al. MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis. *Radiology* 2018;286:547–56.
36. Drummond D, Dana J, Berteloot L, et al. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. *J Cyst Fibros* 2022;21:212–9.
37. Poetter-Lang S, Staufner K, Baltzer P, et al. The efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: a clinical observational cohort study. *Eur Radiol* 2019;29:1048–58.
38. Lewindon PJ, Shepherd RW, Walsh MJ, et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. *Hepatology* 2011;53:193–201.
39. Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. *Arch Dis Child* 1996;75:67–70.
40. Shapira R, Hadzic N, Francavilla R, Koukulis G, Price JF, Mieli-Vergani G. Retrospective review of cystic fibrosis presenting as infantile liver disease. *Arch Dis Child* 1999;81:125–8.
41. Kotalova R, Jirsa M, Vavrova V, Vrabelova-Pouchla S, Macek M Jr. Wilson disease as a cause of liver injury in cystic fibrosis. *J Cyst Fibros* 2009;8:63–5.
42. Ahmad J, Barnhart HX, Bonacini M, et al. Value of liver biopsy in the diagnosis of drug-induced liver injury. *J Hepatol* 2022;76:1070–8.
43. Blanc WA, Di Sant'Agnese PA. A distinctive type of biliary cirrhosis of the liver associated with cystic fibrosis of the pancreas; recognition through signs of portal hypertension. *Pediatrics* 1956;18:387–409 (in English). Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=13359058.
44. Roy CC, Weber AM, Morin CL, et al. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. *J Pediatr Gastroenterol Nutr* 1982;1:469–78.
45. Wilroy RS Jr, Crawford SE, Johnson WW. Cystic fibrosis with extensive fat replacement of the liver. *J Pediatr* 1966;68:67–73.
46. Figueiredo P, Almeida N, Lérias C, et al. Effect of portal hypertension in the small bowel: an endoscopic approach. *Dig Dis Sci* 2008;53:2144–50.
47. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. *Hepatology* 1998;27:166–74.
48. Flass T, Tong S, Frank DN, et al. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. *PLoS One* 2015;10:e0116967.
49. Witters P, Libbrecht L, Roskams T, et al. Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. *J Cyst Fibros* 2017;16:e11–3.
50. Hillaire S, Cazals-Hatem D, Bruno O, et al. Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. *Liver Transpl* 2017;23:1342–7.
51. Dana J, Debray D, Beaufrere A, et al. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. *J Hepatol* 2022;76:420–34.
52. De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. *Lancet Gastroenterol Hepatol* 2019;4:399–411.
53. Craig JM, Haddad H, Shwachman H. The pathological changes in the liver in cystic fibrosis of the pancreas. *AMA J Dis Child* 1957;93:357–69.
54. Isenberg JN. Cystic fibrosis: its influence on the liver, biliary tree, and bile salt metabolism. *Semin Liver Dis* 1982;2:302–13.
55. Strandvik B, Hulcrantz R. Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. *Liver* 1994;14:32–6.
56. Lindblad A, Hulcrantz R, Strandvik B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. *Hepatology* 1992;16:372–81.
57. Furuya KN, Roberts EA, Canny GJ, Phillips MJ. Neonatal hepatitis syndrome with paucity of interlobular bile ducts in cystic fibrosis. *J Pediatr Gastroenterol Nutr* 1991;12:127–30.

58. Tang A, Cloutier G, Szevenyi NM, Sirlin CB. Ultrasound elastography and MR elastography for assessing liver fibrosis: Part 2, diagnostic performance, confounders, and future directions. *AJR Am J Roentgenol* 2015;205:33–40.
59. Breton E, Bridoux-Henno L, Guyader D, et al. [Value of transient elastography in noninvasive assessment in children's hepatic fibrosis]. *Arch Pediatr* 2009;16:1005–10.
60. Behrens CB, Langholz JH, Eiler J, et al. A pilot study of the characterization of hepatic tissue strain in children with cystic-fibrosis-associated liver disease (CFLD) by acoustic radiation force impulse imaging. *Pediatr Radiol* 2013;43:552–7.
61. Canas T, Macia A, Munoz-Codoceo RA, et al. Hepatic and splenic acoustic radiation force impulse shear wave velocity elastography in children with liver disease associated with cystic fibrosis. *Biomed Res Int* 2015;2015:1–7.
62. Friedrich-Rust M, Schlueter N, Smaczny C, et al. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. *J Cyst Fibros* 2013;12:431–9.
63. Karlas T, Neuschulz M, Oltmanns A, et al. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. *PLoS One* 2012;7:e42139.
64. Karlas T, Neuschulz M, Oltmanns A, Wirtz H, Keim V, Wiegand J. ARFI and transient elastography for characterization of cystic fibrosis related liver disease: first longitudinal follow-up data in adult patients. *J Cyst Fibros* 2013;12:826–7.
65. Manco M, Zupone CL, Alghisi F, D'Andrea ML, Lucidi V, Monti L. Pilot study on the use of acoustic radiation force impulse imaging in the staging of cystic fibrosis associated liver disease. *J Cyst Fibros* 2012;11:427–32.
66. Manco M, Lo Zupone C, Latini A, Lucidi V, Monti L. Noninvasive assessment of cystic fibrosis-associated liver disease with acoustic radiation force impulse imaging. *Hepatology* 2011;53:1779–80.
67. Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. *Can J Gastroenterol Hepatol* 2015;29:139–44.
68. Monti L, Manco M, Lo Zupone C, et al. Acoustic radiation force impulse (ARFI) imaging with Virtual Touch Tissue Quantification in liver disease associated with cystic fibrosis in children. *Radiol Med* 2012;117:1408–18.
69. Calvopina DA, Noble C, Weis A, et al. Supersonic shear-wave elastography and APRI for the detection and staging of liver disease in pediatric cystic fibrosis. *J Cyst Fibros* 2020;19:449–54.
70. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. *J Magn Reson Imaging* 2013;37:544–55.
71. Sawh MC, Newton KP, Goyal NP, et al. Normal range for MR elastography measured liver stiffness in children without liver disease. *J Magn Reson Imaging* 2020;51:919–27.
72. Dana J, Girard M, Franchi-Abella S, et al. Comparison of transient elastography, shearwave elastography, magnetic resonance elastography and fibrotest as routine diagnostic markers for assessing liver fibrosis in children with cystic fibrosis. *Clin Res Hepatol Gastroenterol* 2022;46:101855.
73. Hayes D Jr, Krishnamurthy R, Hu HH. Magnetic resonance elastography demonstrates elevated liver stiffness in cystic fibrosis patients. *J Cyst Fibros* 2018;17:e54–6.
74. de Ledinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. *J Pediatr Gastroenterol Nutr* 2007;45:443–50.
75. Lewindon PJ, Puertolas-Lopez MV, Ramm LE, et al. Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis. *Clin Gastroenterol Hepatol* 2019;17:2561–69.e5.
76. Bader RM, Jonas MM, Mitchell PD, Wiggins S, Lee CK. Controlled attenuation parameter: a measure of hepatic steatosis in patients with cystic fibrosis. *J Cyst Fibros* 2019;18:280–5.
77. Ye W, Leung DH, Mollleston JP, et al. Association between transient elastography and controlled attenuated parameter and liver ultrasound in children with cystic fibrosis. *Hepatology Commun* 2021;5:1362–72.
78. Debray D, Lykavieris P, Gauthier F, et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. *J Hepatol* 1999;31:77–83.
79. Ye W, Narkewicz MR, Leung DH, et al. Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis. *J Pediatr Gastroenterol Nutr* 2018;66:122–7.
80. Pals FH, Verkade HJ, Gulmans VAM, et al. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands. *J Cyst Fibros* 2019;18:385–9.
81. Toledano MB, Mukherjee SK, Howell J, et al. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. *PLoS One* 2019;14:e0212779.
82. Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? *J Pediatr Gastroenterol Nutr* 1997;25:32–6 (in English). Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9226524.
83. Lemoine C, Lokar J, McColley SA, Alonso EM, Superina R. Cystic fibrosis and portal hypertension: distal splenorenal shunt can prevent the need for future liver transplant. *J Pediatr Surg* 2019;54:1076–82.
84. Freeman AJ, Sellers ZM, Mazariegos G, et al. A multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis-associated liver disease. *Liver Transpl* 2019;25:640–57.
85. Desai CS, Gruessner A, Habib S, Gruessner R, Khan KM. Survival of cystic fibrosis patients undergoing liver and liver-lung transplantations. *Transplant Proc* 2013;45:290–2.
86. Chow KU, Luxembourg B, Seifried E, Bonig H. Spleen size is significantly influenced by body height and sex: establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals. *Radiology* 2016;279:306–13.
87. Rosenberg HK, Markowitz RI, Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic size in infants and children: sonographic measurements. *AJR Am J Roentgenol* 1991;157:119–21.
88. Calle-Toro JS, Back SJ, Viteri B, Andronikou S, Kaplan SL. Liver, spleen, and kidney size in children as measured by ultrasound: a systematic review. *J Ultrasound Med* 2020;39:223–30.
89. Stonebraker JR, Ooi CY, Pace RG, et al. Features of severe liver disease with portal hypertension in patients with cystic fibrosis. *Clin Gastroenterol Hepatol* 2016;14:1207–15.e3.
90. Kim DW, Yoon HM, Jung AY, et al. Diagnostic performance of ultrasound elastography for evaluating portal hypertension in children: a systematic review and meta-analysis. *J Ultrasound Med* 2019;38:747–59.
91. Mandorfer M, Hernandez-Gea V, Garcia-Pagan JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. *Semin Liver Dis* 2020;40:240–55.
92. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015;63:743–52.
93. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. *J Hepatol* 2006;44:111–7.
94. Shneider BL, Bosch J, de Franchis R, et al. Portal hypertension in children: expert pediatric opinion on the report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. *Pediatr Transplant* 2012;16:426–37.
95. Martin CR, Zaman MM, Ketwaroo GA, et al. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. *Am J Physiol Gastrointest Liver Physiol* 2012;303:G474–81.
96. Bass LM, Shneider BL, Henn L, Goodrich NP, Magee JC; Childhood Liver Disease Research Network. Clinically evident portal hypertension: an operational research definition for future investigations in the pediatric population. *J Pediatr Gastroenterol Nutr* 2019;68:763–7.
97. Williams SM, Goodman R, Thomson A, McHugh K, Lindsell DR. Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. *Clin Radiol* 2002;57:365–70.
98. Curry MP, Hegarty JE. The gallbladder and biliary tract in cystic fibrosis. *Curr Gastroenterol Rep* 2005;7:147–53 (in English). Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15802104.

99. Buxbaum J, Nguyen N, Kulkarni S, Palmer S, Rao A, Selby R. Multidisciplinary treatment of cystic fibrosis-related recurrent pyogenic cholangitis (CF-RPC). *Dig Dis Sci* 2015;60:1801–4.
100. Gaskin KJ, Waters DL, Howman-Giles R, et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. *N Engl J Med* 1988;318:340–6.
101. O'Brien S, Keogan M, Casey M, et al. Biliary complications of cystic fibrosis. *Gut* 1992;33:387–91.
102. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. *J Natl Cancer Inst* 2013;105:122–9.
103. McKeon D, Day A, Parmar J, Alexander G, Bilton D. Hepatocellular carcinoma in association with cirrhosis in a patient with cystic fibrosis. *J Cyst Fibros* 2004;3:193–5.
104. Kelleher T, Staunton M, O'Mahony S, McCormick PA. Advanced hepatocellular carcinoma associated with cystic fibrosis. *Eur J Gastroenterol Hepatol* 2005;17:1123–4.
105. O'Donnell DH, Ryan R, Hayes B, Fennelly D, Gibney RG. Hepatocellular carcinoma complicating cystic fibrosis related liver disease. *J Cyst Fibros* 2009;8:288–90.
106. O'Brien C, Ramlal N, Haughey A, Nolan N, Malone DE, McCormick PA. Hepatocellular carcinoma in cystic fibrosis liver disease: a cautionary tale. *QJM* 2019;112:693–4.
107. Yamada A, Komaki Y, Komaki F, Micic D, Zullo S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. *Lancet Oncol* 2018;19:758–67.
108. Fink AK, Yanik EL, Marshall BC, et al. Cancer risk among lung transplant recipients with cystic fibrosis. *J Cyst Fibros* 2017;16:91–7.

Disclaimer

ESPGHAN is not responsible for the practices of physicians and provides guidelines and position papers as indicators of best practice only. Diagnosis and treatment is at the discretion of physicians.

The NASPGHAN clinical practice guidelines and position papers are evidence-based decision-making tools for managing health conditions. This document is not a disease management requirement or rule and should not be construed as establishing a legal standard of care, or as encouraging, advocating for, mandating or discouraging any particular diagnostic methodology or treatment. Our clinical practice guidelines and position papers should also not be used in support of medical complaints, legal proceedings, and/or litigation, as they were not designed for this purpose. The NASPGHAN clinical practice guidelines and position papers should also not be utilized by insurance companies or pharmacy benefit managers to

deny treatment that is deemed medically necessary by a patient's physician. The health care team, patient, and family should make all decisions regarding the care of a patient, after consideration of individual specific medical circumstances. While NASPGHAN makes every effort to present accurate and reliable evidence-based information, these clinical practice guidelines and position papers are provided "as is" without any warranty of accuracy, reliability, or otherwise, either express or implied. NASPGHAN does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither NASPGHAN nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, nor consequential damages, incurred in connection with the clinical practice guidelines and/or position papers or reliance on the information presented.